Alliance Global Partners lowered shares of Viveve Medical (NASDAQ:VIVE – Get Rating) from a buy rating to a neutral rating in a report issued on Monday morning, The Fly reports.
Viveve Medical Price Performance
Shares of NASDAQ:VIVE opened at $0.10 on Monday. The company's fifty day moving average price is $0.45 and its 200-day moving average price is $0.61. The firm has a market capitalization of $1.04 million, a price-to-earnings ratio of -0.04 and a beta of 0.35. Viveve Medical has a one year low of $0.09 and a one year high of $1.24.
Get Viveve Medical alerts:Viveve Medical (NASDAQ:VIVE – Get Rating) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.59) EPS for the quarter. The company had revenue of $1.68 million during the quarter. Viveve Medical had a negative return on equity of 306.23% and a negative net margin of 355.33%.
Viveve Medical Company Profile
(Get Rating)
Viveve Medical, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components.
Featured Articles
- Get a free copy of the StockNews.com research report on Viveve Medical (VIVE)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.
